Nabla Announces Exclusive Partnership With Advanced Machine Intelligence to Pioneer the Next Era of Agentic Healthcare AI

Nabla, one of the most advanced AI assistants in clinical care, led by Alexandre Lebrun, Delphine Groll, Martin Raison, Laurent Landowski, and others, has announced an exclusive strategic partnership with Advanced Machine Intelligence, the new AI research company founded by Professor Yann LeCun. This next chapter builds on LeCun’s early belief in Nabla’s mission and his continued confidence in the company’s technical vision. As part of a board-supported transition, Nabla co-founder Alex LeBrun will move to CEO of Advanced Machine Intelligence and assume the roles of Chief AI Scientist and Chairman at Nabla, overseeing long-term technical strategy. Co-founder and COO Delphine Groll will continue leading day-to-day operations while a permanent CEO is sought.

Through the partnership, Nabla will gain early access to Advanced Machine Intelligence’s emerging world model technologies, positioning the company to lead in FDA-certifiable agentic AI for healthcare.

“Healthcare AI is entering an era where reliability, determinism, and simulation are as critical as linguistic intelligence,” said Alex LeBrun, co-founder and CEO of Nabla. The collaboration provides privileged access to world model technology to complement existing LLMs and support safe, autonomous systems for clinicians.

Current healthcare AI, largely powered by LLMs, has improved documentation and workflow support but faces limitations such as hallucinations, non-deterministic reasoning, and difficulty processing continuous multimodal data, constraining autonomous decision-making.

Since 2018, Nabla has pioneered machine learning systems for clinical environments, predating GPT-3, and continues to drive innovation through this partnership.

World models represent the next leap, enabling deterministic, auditable decisions, simulation-based reasoning, robust handling of continuous medical signals, and a credible regulatory path for autonomous agentic systems. Combined with LLMs, they form the foundation for safe, actionable clinical AI.

“Nabla has consistently anticipated the promise and limits of LLMs in medicine, prioritizing safety, usability, and real-world deployment,” said Yann LeCun, Founder of Advanced Machine Intelligence. “Their leadership makes them the ideal partner for this next phase of healthcare AI innovation.”

In the coming months, Nabla will expand its ambient AI assistant, enhance product quality, and invest in multimodality, simulation, and deterministic reasoning, preparing the next generation of agentic systems.

“This marks a natural next chapter in Nabla’s long-term strategy,” said Delphine Groll. “The mission remains to deliver the most advanced, reliable, and clinically meaningful AI assistant to healthcare, supported by a strong team, roadmap, and momentum.”